Hormonal
GLP-1 receptor agonists (specifically semaglutide and liraglutide) improve liver histology in MASH patients, with semaglutide demonstrating the strongest evidence for resolving steatohepatitis without worsening fibrosis.
If you have MASH, GLP-1 medications like semaglutide are currently the most evidence-backed pharmacological option to improve liver health, potentially resolving the disease without worsening scarring. This is particularly relevant if you also have Type 2 Diabetes or obesity, as these drugs address the underlying metabolic drivers. While weight loss contributes, the histological benefits appear to extend beyond weight reduction alone.
Among GLP-1RAs, semaglutide has the strongest evidence of liver histological benefit... In the liraglutide group, 9% of patients achieved resolution of NASH with liraglutide (vs. 9% with placebo, p = .019)... By week 72, 40%, 36% and 59% of patients achieved biopsy-confirmed NASH resolution without worsening of fibrosis in the semaglutide 0.1 mg, 0.2 mg and 0.4 mg groups, respectively (vs. 17% with placebo).
Why this rating
Based on multiple phase 2 RCTs (LEAN, Newsome et al.) and a proof-of-concept trial, though large-scale phase 3 definitive data is still ongoing.
Source
The role of glucagon‐like peptide‐1 receptor agonists in metabolic dysfunction‐associated steatohepatitis
Manal F. Abdelmalek et al. · Diabetes Obesity and Metabolism · 2024
DOI 10.1111/dom.15524
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →